Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kathryn E. Vanderlaag
Observed names:
Kathryn E Vanderlaag,
Kathryn Vanderlaag
Observed institutions:
Bristol-Myers Squibb (United States),
Notable Labs (United States),
Regend Therapeutics (China),
Texas A&M University
OpenAlex ID:
A5060461293
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-α and survivin
2010
·
Kathryn E Vanderlaag
, Susan Hudak
, et al.
·
Breast Cancer Research
·
114
PDF
Vascular Endothelial Growth Factor Receptor-2 Expression Is Induced by 17β-Estradiol in ZR-75 Breast Cancer Cells by Estrogen Receptor α/Sp Proteins
2006
·
Kelly J. Higgins
, Shengxi Liu
, et al.
·
Endocrinology
·
54
Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17β-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor α/Sp Proteins
2007
·
Kelly J. Higgins
, Shengxi Liu
, et al.
·
Molecular Endocrinology
·
39
1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice
2007
·
Yunpeng Su
, Kathryn Vanderlaag
, et al.
·
Breast Cancer Research
·
22
PDF
Regenerating islet‐derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer
2011
·
Kathryn Vanderlaag
, Wei Wang
, et al.
·
International Journal of Cancer
·
21
PDF
Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes
2023
·
Meagan A. Jacoby
, John S. Welch
, et al.
·
Cancer Research
·
2
Development of a multiomics and functional drug sensitivity platform to investigate cell type specific drug effects in AML.
2021
·
Marianne T. Santaguida
, Ryosuke Kita
, et al.
·
Journal of Clinical Oncology
·
1
Abstract 338: Innovative strategy for enhancing the reach of HER3 antibody-drug conjugates: A novel drug combination approach
2025
·
Kathryn E. Vanderlaag
, Anukriti Dhar
, et al.
·
Cancer Research
Abstract 5092: Development of a priming approach to enhance antigen-directed therapies in hematological malignancies and solid tumors
2024
·
Kathryn E. Vanderlaag
, Anukriti Dhar
, et al.
·
Cancer Research
Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
2023
·
Tara L. Lin
, Robyn Wood
, et al.
·
Journal of Clinical Oncology
Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
2022
·
Tara L. Lin
, Robyn Wood
, et al.
·
Journal of Clinical Oncology
Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay
2021
·
Markus D Lacher
, Michelle A Richardson
, et al.
·
Blood
Abstract 2707: Integrated analysis of colorectal carcinoma by co-extraction of RNA, DNA and protein from FFPE tumor samples
2018
·
Vishal Patel
, Ji Gao
, et al.
·
Cancer Research
Mechanisms of growth inhibition induced by methylene-substituted and ring-substituted dims in breast cancer cells
2009
·
Kathryn Vanderlaag
·
OakTrust (Texas A&M University Libraries)
Inhibition of estrogen receptor negative breast cancer cell growth by a new class of peroxisome proliferator-activated receptor γ agonists
2004
·
Kathryn Vanderlaag
, Kelcey Walker
, et al.
·
Cancer Research
Show more works
View as search
Works count:
15
Citation count:
253
H-index:
5
I10-index:
5
Year
Topic
Type
